An optimized formulation of glucagon-like peptide-1 recombinantly fused to an elastin-like polypeptide leads to zero-order release kinetics from a subcutaneous depot and to 10 days of glycaemic control in three mouse models of diabetes.
- Kelli M. Luginbuhl
- Jeffrey L. Schaal
- Ashutosh Chilkoti
